Guidance

Meningococcal group B (4CMenB) vaccine for prevention of gonorrhoea for GBMSM: PGD template

Patient group direction (PGD) template to support the provision of 4CMenB vaccine to gay, bisexual, and men who have sex with men (GBMSM).

• From: UK Health Security Agency
• Published: 1 July 2025

Applies to England

Documents

Meningococcal group B (4CMenB) vaccine for prevention of gonorrhoea for GBMSM: PGD template

Ref: UKHSA gateway number GOV-18571

MS Word Document, 142 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The new PGD will enable the administration of meningococcal group B vaccine (rDNA, component, adsorbed) (4CMenB) to gay, bisexual, and other men who have sex with men (GBMSM) who are at higher risk of gonorrhoea, in accordance with national recommendations in the UK, JCVI, Green Book Gonorrhoea chapter and Bipartite letter.

The Gonorrhoea PGD version 1.00 is valid from 1 August 2025 to 1 August 2027.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 1 July 2025